Citadel Advisors
PPH icon

Citadel Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Citadel Advisors’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$437K Buy
+4,000
New +$414K ﹤0.01% 10213
2026
Q1 		– Sell
-3,200
Closed -$330K – 13955
2025
Q4 		$330K Buy
+3,200
New +$311K ﹤0.01% 9936
2025
Q3 		– Sell
-6,100
Closed -$537K – 13804
2025
Q2 		$537K Buy
6,100
+3,800
+165% +$329K ﹤0.01% 8459
2025
Q1 		$210K Buy
2,300
+100
+5% +$9.01K ﹤0.01% 10355
2024
Q4 		$190K Buy
2,200
+1,200
+120% +$109K ﹤0.01% 10541
2024
Q3 		$95K Sell
1,000
-300
-23% -$28.5K ﹤0.01% 11184
2024
Q2 		$119K Sell
1,300
-100
-7% -$8.93K ﹤0.01% 10663
2024
Q1 		$127K Buy
1,400
+1,100
+367% +$96.3K ﹤0.01% 11025
2023
Q4 		$24.4K Hold
300
– – ﹤0.01% 12453
2023
Q3 		$24K Sell
300
-2,600
-90% -$210K ﹤0.01% 12475
2023
Q2 		$228K Sell
2,900
-2,700
-48% -$211K ﹤0.01% 9589
2023
Q1 		$435K Buy
5,600
+5,400
+2,700% +$416K ﹤0.01% 8591
2022
Q4 		$15.5K Sell
200
-38,500
-99% -$2.84M ﹤0.01% 13321
2022
Q3 		$2.6M Buy
38,700
+11,700
+43% +$862K ﹤0.01% 5093
2022
Q2 		$2.08M Buy
+27,000
New +$2.11M ﹤0.01% 5473
2021
Q4 		– Sell
-3,800
Closed -$276K – 14519
2021
Q3 		$276K Buy
+3,800
New +$283K ﹤0.01% 11233
2021
Q2 		– Sell
-16,200
Closed -$1.12M – 14244
2021
Q1 		$1.12M Sell
16,200
-2,900
-15% -$200K ﹤0.01% 7832
2020
Q4 		$1.27M Buy
19,100
+13,300
+229% +$852K ﹤0.01% 6284
2020
Q3 		$361K Buy
+5,800
New +$367K ﹤0.01% 7822
2019
Q3 		– Sell
-5,400
Closed -$317K – 9630
2019
Q2 		$317K Sell
5,400
-6,100
-53% -$353K ﹤0.01% 7500
2019
Q1 		$698K Buy
+11,500
New +$680K ﹤0.01% 6221

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Citadel Advisors's PPH Position: Q2 2026 in Review

Citadel Advisors reduced its VanEck Pharmaceutical ETF (PPH) stake by 51% in Q2 2026, selling an estimated $3.51M and leaving 33,171 shares worth $3.63M. The position accounts for ﹤0.01% of the portfolio, ranked #5305.

Citadel Advisors first reported a position in PPH in Q1 2014 and has held it in 47 quarters since. The position peaked at $6.97M in Q1 2026. 147 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

  • Citadel Advisors held 33,171 shares of VanEck Pharmaceutical ETF worth $3.63M as of Q2 2026.
  • Citadel Advisors sold 33,915 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $3.51M.
  • VanEck Pharmaceutical ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5305 holding.
  • Citadel Advisors first reported a position in VanEck Pharmaceutical ETF in Q1 2014 and has held it in 47 quarters since.
  • Citadel Advisors's VanEck Pharmaceutical ETF position peaked at $6.97M in Q1 2026.
  • 147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.